| pubmed-article:17042387 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17042387 | lifeskim:mentions | umls-concept:C0007450 | lld:lifeskim |
| pubmed-article:17042387 | lifeskim:mentions | umls-concept:C0042036 | lld:lifeskim |
| pubmed-article:17042387 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:17042387 | lifeskim:mentions | umls-concept:C0086045 | lld:lifeskim |
| pubmed-article:17042387 | lifeskim:mentions | umls-concept:C0001339 | lld:lifeskim |
| pubmed-article:17042387 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:17042387 | lifeskim:mentions | umls-concept:C2745888 | lld:lifeskim |
| pubmed-article:17042387 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17042387 | pubmed:dateCreated | 2006-10-17 | lld:pubmed |
| pubmed-article:17042387 | pubmed:abstractText | The purpose of this study was to compare the clinical utility of the serum concentration of feline trypsin-like immunoreactivity (fTLI), the plasma and urine concentrations of trypsinogen-activation peptide (TAP), and the ratio of the urine TAP and creatinine concentrations (TAP:Cr) in the diagnosis of feline acute pancreatitis. We used 13 healthy cats and 10 cats with a diagnosis of acute pancreatitis. The mean serum fTLI and plasma TAP concentrations were significantly higher in the cats with acute pancreatitis than in the healthy cats (P < 0.05); the mean urine TAP concentrations and the median urine TAP:Cr ratios were not significantly different. Among the cats examined in this study, there was no benefit of plasma TAP over serum fTLI in the evaluation of suspected acute pancreatitis. | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17042387 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17042387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17042387 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17042387 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17042387 | pubmed:issn | 0830-9000 | lld:pubmed |
| pubmed-article:17042387 | pubmed:author | pubmed-author:WilliamsDavid... | lld:pubmed |
| pubmed-article:17042387 | pubmed:author | pubmed-author:BroussardJohn... | lld:pubmed |
| pubmed-article:17042387 | pubmed:author | pubmed-author:SteinerJörgJ | lld:pubmed |
| pubmed-article:17042387 | pubmed:author | pubmed-author:JonesBoydB | lld:pubmed |
| pubmed-article:17042387 | pubmed:author | pubmed-author:AllenHeidi... | lld:pubmed |
| pubmed-article:17042387 | pubmed:author | pubmed-author:MansfieldCaro... | lld:pubmed |
| pubmed-article:17042387 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17042387 | pubmed:volume | 70 | lld:pubmed |
| pubmed-article:17042387 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17042387 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17042387 | pubmed:pagination | 313-6 | lld:pubmed |
| pubmed-article:17042387 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:meshHeading | pubmed-meshheading:17042387... | lld:pubmed |
| pubmed-article:17042387 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17042387 | pubmed:articleTitle | Serum and urine concentrations of trypsinogen-activation peptide as markers for acute pancreatitis in cats. | lld:pubmed |
| pubmed-article:17042387 | pubmed:affiliation | The Bobst Hospital, Animal Medical Center, New York, New York 10021, USA. RUN.DVM@Verizon.net | lld:pubmed |
| pubmed-article:17042387 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17042387 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
